Bronstein, Gewirtz & Grossman, LLC Notifies Shareholders of ARS Pharmaceuticals, Inc. (SPRY) InvestigationBusiness Wire • 05/10/23
ARS Pharmaceuticals Announces Availability of Briefing Documents for FDA Advisory Committee Meeting on neffy® for the Treatment of Type I Allergic Reactions Including AnaphylaxisGlobeNewsWire • 05/09/23
ARS Pharmaceuticals Announces FDA Advisory Committee for neffy® for the Treatment of Allergic Reactions (Type 1), Including AnaphylaxisGlobeNewsWire • 03/28/23
ARS Pharmaceuticals Highlights Progress and Reports Fourth Quarter and Full Year 2022 Financial ResultsGlobeNewsWire • 03/23/23
ARS Pharmaceuticals Announces Presentation of Data Supporting neffy (epinephrine nasal spray) and Real-World Burden of Needle InjectorsGlobeNewsWire • 02/23/23